Biomea Fusion, Inc. (BMEA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 40.78M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 6.95M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -58.06M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $40.78M | (m) | $6.95M | $-58.06M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $48.20M | (m) | $7.93M | $-66.57M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $61.98M | (m) | $9.52M | $-83.51M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $79.10M | (m) | $12.17M | $-101.87M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $91.95M | (m) | $14.97M | $-115.10M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $107.21M | (m) | $17.24M | $-132.72M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $118.08M | (m) | $19.09M | $-144.07M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $123.71M | (m) | $18.47M | $-151.32M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $121.81M | (m) | $17.32M | $-148.40M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $111.93M | (m) | $15.92M | $-137.16M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $102.55M | (m) | $14.13M | $-126.14M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $92.22M | (m) | $12.98M | $-115.08M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $85.11M | (m) | $12.12M | $-107.45M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $75.76M | (m) | $11.24M | $-97.27M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $62.71M | (m) | $10.34M | $-83.63M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $53.26M | (m) | $9.55M | $-72.09M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $42.91M | (m) | $8.74M | $-61.25M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $35.55M | (m) | $7.64M | $-52.21M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $28.00M | (m) | $6.23M | $-41.67M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $3.67M | (m) | $322.00K | $-5.33M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $1.09M | (m) | (m) | $-1.20M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |